Pyxis Oncology prices Nasdaq IPO at $16/share
LONDON, UK: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Pyxis Oncology Inc., has announced the pricing of its initial public offering of 10.5 million shares of common stock at a public offering price of $16 per share for aggregate gross proceeds of $167.2m million.
In addition, Pyxis has granted the underwriters an option for a period of 30 days to purchase up to 1.575 million additional shares of common stock. All of the shares are being offered by Pyxis. Pyxis’ common stock is expected to begin trading on the Nasdaq Global Market on 8 October 2021 under the ticker symbol “PYXS”.
The IPO resulted in an £7.9million (553p per share) increase in the value of Arix’s existing holding in Pyxis, which was valued at £10.8 million at 30 June 2021. Mark Chin, Arix Managing Director, will continue to serve on Pyxis’ board.
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.
Arix Bioscience PLC share price
140.00 GBX−2.00 (1.41%)today
7 Oct, 5:35 pm GMT+1 ·Disclaimer
About The Author
